Does insurance cover Mounjaro in Pennsylvania?

If you’ve been prescribed a GLP-1 medication like Wegovy, Ozempic, or Mounjaro, you’re probably wondering: Will my insurance actually pay for this? The short answer is: it depends—on your insurance type, your diagnosis, and even where you live. In 2025, coverage for these highly effective medications remains a complex patchwork of approvals, denials, and strict requirements.

This guide will walk you through exactly what insurance companies cover, which states’ Medicaid programs still pay for weight-loss GLP-1s, and what to do if your claim gets denied. We’ll also break down the best self-pay options and savings programs available right now, so you can make an informed decision about your treatment.

Understanding GLP-1 Medications: What’s the Difference?

Before diving into insurance coverage, let’s clarify what these medications are and why insurers treat them differently.

Wegovy (semaglutide) is FDA-approved specifically for chronic weight management in adults with obesity (BMI ≥30) or overweight adults (BMI ≥27) who have at least one weight-related health condition like high blood pressure or Type 2 diabetes.

Ozempic (also semaglutide) is FDA-approved for Type 2 diabetes management and cardiovascular risk reduction. While it’s chemically identical to Wegovy and causes weight loss, insurers will only cover it for its approved diabetes indication—not for weight loss alone.

Mounjaro (tirzepatide) is similarly approved for Type 2 diabetes. Eli Lilly markets a higher-dose version called Zepbound for obesity, but Mounjaro itself is only covered when prescribed for diabetes.

This distinction matters enormously for insurance coverage. Most plans will cover diabetes medications as essential health benefits but treat obesity drugs as optional—and expensive—add-ons that many employers choose to exclude.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

Commercial Insurance Coverage: The Reality for Most Americans

Does Private Insurance Cover Weight-Loss GLP-1s?

The truth: Coverage for Wegovy and other obesity medications under commercial insurance is limited and highly restricted. According to a 2024 KFF analysis, many employer-sponsored plans exclude weight-loss drugs entirely due to their high cost—often $1,000+ per month. When coverage does exist, it comes with significant hurdles.

Typical Coverage Requirements

If your commercial plan does cover Wegovy, expect to meet all of these criteria:

Prior Authorization (PA) is Almost Always Required
Nearly 100% of plans require prior authorization. Your doctor must submit documentation proving medical necessity, including:

• BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (Type 2 diabetes, hypertension, high cholesterol, sleep apnea, etc.)
• Evidence of at least 6 months of supervised diet and lifestyle modification attempts
• Detailed weight history and current health status

Step Therapy Protocols
Many insurers require you to try older, cheaper weight-loss medications first (like phentermine or orlistat) before approving a GLP-1. Some plans mandate trying Saxenda (liraglutide) before Wegovy, since both are made by Novo Nordisk but Saxenda has been available longer.

For diabetes medications like Ozempic or Mounjaro, step therapy typically means proving you’ve tried metformin or another first-line diabetes drug without adequate blood sugar control.

Ongoing Monitoring Requirements
Initial approval is often for just 3–6 months. To continue coverage, you must demonstrate meaningful weight loss—typically at least 5% of baseline body weight—and attend regular follow-up appointments. Missing these checkpoints can result in coverage termination.

What About Ozempic and Mounjaro for Diabetes?

Here’s the good news: If you have Type 2 diabetes, Ozempic and Mounjaro are widely covered under most commercial plans’ pharmacy benefits. They’re treated like other essential diabetes medications (though often placed in higher tiers due to cost).

However, insurers actively prevent off-label use for weight loss. If your prescription for Ozempic indicates weight management rather than diabetes, expect a denial—even if your doctor prescribed it. Prior authorization systems flag non-diabetes uses and require switching to Wegovy if your plan covers obesity treatment at all.

Medicare Coverage: Still No General Obesity Coverage in 2025

The Federal Exclusion Remains in Place

By law, Medicare Part D cannot cover drugs prescribed solely for weight loss. This exclusion has been in place since Medicare Part D launched in 2006 and remains unchanged in 2025.

The One Important Exception

In March 2024, CMS announced that Medicare will cover Wegovy when prescribed for cardiovascular risk reduction in patients with established heart disease and obesity. This follows FDA’s approval of Wegovy to reduce heart attack and stroke risk in this specific population.

What this means: If you have obesity plus documented cardiovascular disease (prior heart attack, stroke, peripheral artery disease, etc.), Medicare Part D may cover Wegovy under its cardiovascular indication—not for weight loss per se. Your doctor’s prescription and documentation must clearly support this use.

For general weight management without cardiovascular disease, Medicare still offers no coverage for Wegovy, Saxenda, or Zepbound as of 2025.

Diabetes Medications Remain Covered

Medicare Part D does cover Ozempic and Mounjaro for Type 2 diabetes. These are treated as standard diabetes medications on Part D formularies, though often placed on higher tiers (Tier 3 or 4) with significant coinsurance.

Medicaid Coverage: A State-by-State Patchwork Getting Smaller

The Big Picture: Most States Don’t Cover Weight-Loss GLP-1s

Federal Medicaid rules allow states to exclude drugs used for weight loss or weight gain (Social Security Act Section 1905). According to KFF research, only about 13 states covered GLP-1 obesity medications as of late 2024—and that number is shrinking fast due to budget pressures.

State-by-State Breakdown (Priority States)

California: Coverage Ending January 1, 2026

California’s Medi-Cal program added coverage for Wegovy in 2025, requiring prior authorization based on BMI criteria and documented lifestyle interventions. However, facing a massive budget deficit, California announced in December 2025 that Wegovy, Saxenda, and Zepbound will no longer be covered after January 1, 2026 for adults.

Pediatric patients (under 18) can still access these medications through EPSDT (Early and Periodic Screening, Diagnostic and Treatment) provisions, which require broader coverage for children.

Pennsylvania: Also Ending Coverage in January 2026

Pennsylvania Medicaid began covering Wegovy with strict prior authorization in 2024. Criteria included BMI ≥30 or ≥27 with comorbidities, plus documented diet/exercise attempts. Patients with diabetes had to try a diabetes-specific GLP-1 first.

Like California, Pennsylvania announced in December 2025 that coverage will end in January 2026 due to unsustainable costs. This affects tens of thousands of enrollees who gained access over the past year.

Texas: Never Covered

Texas Medicaid explicitly excludes all obesity medications for adults age 21 and older. This policy has been in place since at least March 2023. Wegovy, Saxenda, Qsymia, and similar drugs are not on the Texas Vendor Drug Program formulary.

Patients under 21 may request coverage through EPSDT exceptions on a case-by-case basis, but adult Medicaid enrollees have no pathway to coverage.

Florida: No Coverage

Florida Medicaid does not cover any weight-loss medications. The state uses the federal optional exclusion for obesity drugs. Only GLP-1s prescribed for Type 2 diabetes (Ozempic, Mounjaro) are covered under their diabetes indication.

New York: Still Covering with Prior Authorization

New York’s Medicaid program continues to cover Wegovy as of 2025 under its anti-obesity agents category. Prior authorization requires:

• BMI ≥30 or BMI ≥27 with weight-related comorbidity
• Age ≥18
• Documentation of lifestyle modification
• Quantity limits (typically 4 pens per 28 days)

New York is one of the few states maintaining coverage despite budget concerns, though utilization management remains strict.

Illinois: No Coverage

Illinois Medicaid does not cover weight-loss medications. While Illinois expanded coverage for state employees in 2023, Medicaid enrollees remain excluded from obesity drug coverage.

Common Medicaid Prior Authorization Requirements

For states that do cover these medications, expect to meet criteria similar to commercial insurance:

• BMI thresholds (usually ≥30 or ≥27 + comorbidity)
• Documented 6-month supervised weight-loss program
• Age restrictions (many programs start at 18+, though EPSDT can cover younger patients)
• Periodic re-evaluation (every 3–6 months) with required weight-loss benchmarks
• Quantity limits aligned with FDA dosing schedules

Why Do Denials Happen? (And How to Fight Them)

Top Reasons Insurance Denies GLP-1 Coverage

1. BMI Doesn’t Meet Threshold
If your documented BMI is 29 and you don’t have qualifying comorbidities, most plans will deny Wegovy automatically. Ensure your medical records accurately reflect your current weight and height.

2. Insufficient Documentation of Prior Attempts
‘I tried to lose weight on my own’ isn’t enough. Insurers want to see formal documentation: appointments with dietitians, supervised exercise programs, medically supervised diets, or records of prior weight-loss medication trials spanning at least 6 months.

3. Off-Label Use
Prescribing Ozempic or Mounjaro for weight loss in non-diabetic patients triggers automatic denials. Insurers require the FDA-approved obesity medication (Wegovy or Zepbound) if you don’t have diabetes—and many plans don’t cover those at all.

4. Plan Exclusion
Many employer plans explicitly exclude ‘weight control’ drugs from their formulary. No amount of documentation will overcome a blanket exclusion unless your employer specifically adds obesity treatment coverage.

5. Step Therapy Not Completed
If your plan requires trying phentermine or Saxenda first and your doctor skipped that step, the claim will be denied until you complete the required trial.

How to Appeal a Denial Successfully

1. Gather Complete Documentation
Compile:

• Detailed weight history and BMI calculations
• Records of supervised diet/exercise programs
• Documentation of weight-related comorbidities (lab results, diagnosis codes)
• Letters from treating physicians explaining medical necessity
• Evidence of previous weight-loss medication trials (if applicable)

2. Submit a Formal Appeal Within the Deadline
Most insurers allow 180 days for appeals. Submit in writing, including all supporting documentation and a letter of medical necessity from your prescribing provider.

3. Emphasize Medical Necessity
Focus on health risks: uncontrolled diabetes, cardiovascular disease, severe sleep apnea, etc. The more you can frame weight loss as medically essential rather than cosmetic, the stronger your case.

4. Consider External Review
If your internal appeal fails and you believe the denial was inappropriate, most states allow independent external review. Your state insurance department can provide information on this process.

Success rates vary, but thorough documentation and persistence do overturn denials—especially when clinical criteria are genuinely met but were initially overlooked or inadequately documented.

Telehealth Coverage: Good News for Remote Care

Insurance Generally Covers Telehealth Visits

One bright spot: Most insurance plans now cover telehealth consultations for weight management and chronic disease care. Over 40 states have enacted telehealth parity laws requiring private insurers to cover virtual visits on par with in-person care.

What This Means for GLP-1 Treatment

• Initial consultations, medication management, and follow-up visits can typically be done via secure video platforms
• Nutritional counseling for obesity is an ACA-mandated preventive service—covered even when done remotely
• Medicare expanded telehealth coverage during COVID and has made many changes permanent for chronic care management
• Check that your telehealth provider is in-network; out-of-network telehealth may have higher copays or not be covered

Important Considerations

Verify Network Status
Platforms like Klarity Health may operate as cash-pay services for the consultation itself, even though prescriptions can then be filled through your insurance. Always confirm how billing works before your appointment.

Prescription Fulfillment vs. Visit Coverage
Your telehealth visit may be covered by insurance, but the medication prescribed (like Wegovy) might still require prior authorization or may not be covered at all. These are separate coverage decisions.

Documentation Standards
Insurance companies typically require live video interaction (not just phone calls or messaging) to reimburse telehealth visits at the same rate as in-person care.

What If Insurance Won’t Cover Your Medication? Self-Pay Options That Actually Work

Manufacturer Discount Programs (Updated for 2025)

Novo Nordisk Programs:

For Commercially Insured Patients:

• Wegovy Savings Card: Can reduce copay to as low as $0 (saves up to $225 per month)
• Ozempic Savings Card: For Type 2 diabetes patients; copay as low as $25/month with commercial insurance
• Not valid with government insurance (Medicare, Medicaid)

For Uninsured/Cash-Pay Patients:

• Wegovy Access Program: Now $349/month at retail pharmacies (down from $499 in 2024)
• Ozempic: Lower maintenance doses now ~$349/month through NovoCare
• Patient Assistance Program: Free medication for qualifying low-income patients without insurance

Eli Lilly Programs:

• Mounjaro Savings Card: $25/month for patients with commercial insurance and Type 2 diabetes (covers up to $500)
• Zepbound Vials (cash pay): Single-dose vials now $299–$449 depending on dose (down from $549)
• LillyDirect: Lilly’s direct-to-consumer platform offering lower self-pay pricing
• Patient assistance for qualifying low-income individuals

GoodRx’s Groundbreaking New Pricing (November 2025)

In partnership with Novo Nordisk, GoodRx launched an industry-changing program:

Introductory Pricing:

• $199/month for the first two months of Wegovy or Ozempic
• This applies to most doses, filled at nearly all major pharmacies nationwide

Ongoing Pricing:

• ~$349/month for maintenance doses after the introductory period
• This represents approximately 60-70% off list prices
• Available at CVS, Walgreens, Walmart, and other participating pharmacies

How It Works:

1. Download the GoodRx app or visit GoodRx.com
2. Search for your medication and select the discounted price
3. Show the coupon/code at your pharmacy
4. Cannot be combined with insurance, but no insurance needed

When to Consider Compounded Alternatives (Use Caution)

Some telehealth companies and wellness clinics offer compounded semaglutide or tirzepatide at lower prices ($200–$400/month). Important warnings:

• These are NOT FDA-approved products
• Quality control and potency may vary
• The FDA and manufacturers have raised safety concerns
• Insurance will not cover compounded versions
• Consider this only if brand-name options are completely unaffordable and you understand the risks

Older, Cheaper Weight-Loss Medications

If GLP-1s remain out of reach financially, discuss these options with your doctor:

• Phentermine: Generic stimulant appetite suppressant; typically $30–$50/month
• Orlistat (Alli/Xenical): Fat absorption blocker; ~$50–$100/month
• Phentermine/Topiramate (Qsymia): Combination medication; ~$150–$200/month
• Naltrexone/Bupropion (Contrave): ~$100–$200/month

These medications are less expensive and often covered by insurance with fewer restrictions—though generally less effective than GLP-1s for significant weight loss.

Working with Klarity Health: Transparent Pricing and Multiple Payment Options

At Klarity Health, we understand how frustrating insurance coverage can be. That’s why we’ve designed our service to work whether you have insurance or need to pay out of pocket.

What We Offer:

Flexible Provider Access
Our licensed healthcare providers are available via secure telehealth visits across most states, making it easy to get expert guidance on weight management and GLP-1 medications without the wait times of traditional clinics.

Transparent Pricing
Unlike many healthcare services, we’re upfront about costs:

• Visit fees are clearly stated before you book
• No surprise bills or hidden charges
• Easy-to-understand pricing whether using insurance or self-pay

We Accept Both Insurance and Cash Pay

• If you have insurance: We can work with many major plans (verify your coverage during booking)
• Cash pay option: Predictable, competitive rates for those without coverage or who prefer not to use insurance
• We’ll help you understand your options and navigate prior authorization if needed

Prescription Support
After your consultation, if your provider determines a GLP-1 medication is appropriate:

• We’ll send prescriptions to your preferred pharmacy
• You can use insurance, manufacturer savings programs, or cash-pay discount cards like GoodRx
• Our team can guide you through accessing manufacturer patient assistance programs if cost is a barrier

The key advantage: You’ll know your options upfront and can make informed decisions about your treatment based on what’s actually available to you, not vague promises about insurance coverage.

Medication Cost Comparison Table

Note: Copays vary significantly by plan. ‘PA required’ means prior authorization is typically mandatory. All prices current as of December 2025.

Key Coverage Takeaways: What You Need to Remember

✅ Commercial insurance covers GLP-1s for diabetes fairly reliably, but weight-loss coverage for Wegovy is limited and requires strict prior authorization with BMI and lifestyle documentation

✅ Medicare Part D still excludes obesity medications, with the single exception of Wegovy for cardiovascular risk reduction in patients with established heart disease

✅ Medicaid coverage is shrinking rapidly—California and Pennsylvania are ending weight-loss GLP-1 coverage in January 2026; only about 10-13 states still cover these medications, and all require stringent PA

✅ Texas, Florida, and Illinois Medicaid do not cover weight-loss medications at all; New York continues coverage with restrictions

✅ Telehealth visits are widely covered by insurance for weight management and chronic disease care, making remote treatment accessible

✅ Self-pay prices dropped significantly in late 2025: GoodRx now offers Wegovy/Ozempic at $199/month for the first two months, then $349/month—down from $1,000+ list prices

✅ Manufacturer savings programs can reduce costs to $0–$25/month for insured patients or provide free medication to qualifying uninsured individuals through patient assistance programs

✅ Denials are common but can be appealed successfully with thorough documentation—persistence and proper medical records matter

Your Next Steps: Getting the Treatment You Need

If you have commercial insurance:

1. Check your plan’s formulary for Wegovy, Ozempic, or Mounjaro coverage
2. Gather documentation of your BMI, comorbidities, and previous weight-loss attempts
3. Work with your provider to submit prior authorization with complete documentation
4. If denied, appeal immediately with supporting medical records

If you have Medicare:

• Discuss with your doctor whether you qualify for Wegovy under its cardiovascular indication
• For diabetes medications (Ozempic/Mounjaro), expect standard Part D coverage with copays
• Consider supplemental coverage if available

If you have Medicaid:

• Check your state’s current policy—coverage is changing rapidly
• If your state ends coverage in 2026, explore manufacturer patient assistance programs
• EPSDT may provide coverage for patients under 21

If paying out of pocket:

• Start with GoodRx’s $199 introductory pricing for Wegovy or Ozempic
• Apply for manufacturer patient assistance programs if you qualify based on income
• Consider starting treatment now while discount programs are available
• Connect with providers like Klarity Health who offer transparent cash-pay pricing

Ready to explore your options? Klarity Health providers can help you navigate insurance coverage, access manufacturer savings programs, and develop a treatment plan that fits your budget. With provider availability across multiple states, transparent pricing for both insurance and cash-pay patients, and support for navigating the complex world of GLP-1 coverage, we’re here to make weight management care more accessible.

Frequently Asked Questions

Q: Can I use my HSA or FSA to pay for GLP-1 medications?
A: Yes, if the medication is prescribed for a diagnosed medical condition (obesity, Type 2 diabetes, cardiovascular risk reduction), it qualifies as an eligible medical expense. Save your receipts and prescription documentation.

Q: What happens if I lose weight and my BMI drops below 30—will insurance stop covering my medication?
A: Possibly. Many plans require ongoing evaluation. However, if you have maintained clinically significant weight loss (typically 5% or more) and your provider documents continued medical necessity, most plans will continue coverage for weight maintenance.

Q: Is there a generic version coming soon?
A: Not in the near future. Patents for semaglutide and tirzepatide extend into the 2030s. Generic versions are likely 8-10+ years away.

Q: Can I switch from Ozempic to Wegovy if my insurance covers one but not the other?
A: They’re the same medication (semaglutide), but insurers treat them as separate drugs based on FDA indication. If your plan covers Ozempic for diabetes but not Wegovy for weight loss, switching won’t help—you’d need obesity coverage added to your plan or would need to pay out of pocket for Wegovy.

Q: What if I move to a state with different Medicaid coverage?
A: Your coverage will change based on your new state’s Medicaid formulary. If moving from a state that covers weight-loss GLP-1s to one that doesn’t (or vice versa), plan ahead and discuss continuity of care with your provider before relocating.

Research Currency Statement
Coverage status, pricing, and policy information verified as of December 17, 2025. Insurance formularies and state Medicaid policies are subject to change with new plan years and state budget decisions. Always verify current coverage with your specific insurance plan.

References

1. Aetna Clinical Policy Bulletin – Weight Loss (BMI 35+) GIP-GLP-1/GLP-1 Agonists PA. May 2024. Available at: www.aetna.com

2. California Department of Health Care Services (DHCS). Medi-Cal Rx Bulletin: GLP-1 Medications for Weight Loss Coverage Changes. December 2025. Available at: www.cmadocs.org

3. Cohen J. Coverage of Weight Loss Drugs by Medicaid Plans Continues to Lag. Forbes. August 7, 2025. Available at: www.forbes.com

4. Kaiser Family Foundation (KFF). Medicaid Coverage of and Spending on GLP-1s. November 4, 2024. Available at: www.kff.org

5. GoodRx. GoodRx Launches New $39 Per Month Weight Loss Telemedicine Subscription and $199 Introductory Cash Price for Ozempic and Wegovy [Press Release]. BusinessWire. November 17, 2025. Available at: www.businesswire.com

Source:

• https://www.aetna.com/products/rxnonmedicare/data/2024/WeightLoss%28BMI%2035%29GIP-GLP-1GLP-1AgonistsPAwithLimit6450-CUDR_05-2024.html#:~:text=%C2%B0Wegovy%3A%20Initial%20therapy%20DOA%3A%207,based%20on%20the%20following%20references
• https://www.singlecare.com/blog/cigna-prior-authorization-weight-loss/#:~:text=Cigna%20coverage%20criteria%20for%20GLP,drugs
• https://www.amwinsconnect.com/news/kaiser-permanenter-coverage-changes-glp-1-drugs-and-anti-obesity-medications-2025#:~:text=drugs%20and%20other%20AOMs%20will,with%20BMI%20less%20than%2040
• https://www.texaschildrenshealthplan.org/2023/04/28/provider-alert-non-formulary-requests-for-obesity-control-drugs#:~:text=for%20obesity%20control%20drugs%20for,Imcivree%2C%20Qysmia%2C%20Saxenda%20and%20Wegovy
• https://www.phlp.org/en/news/pennsylvania-medicaid-covers-newer-weight-loss-drugs#:~:text=Generally%2C%20to%20get%20these%20drugs,CDC%29%20charts
• https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal#:~:text=What%20You%20Need%20to%20Know%3A,Cal%20managed%20care
• https://solutionshortcut.com/medicaid-drug-coverage-by-state-2025-2026-updates/#:~:text=VDP%20PDL%20%26%20criteria%3B%20last,com
• https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal#:~:text=%2A%20Three%20GLP,covered%20after%20January%201%2C%202026
• https://www.forbes.com/sites/joshuacohen/2025/08/07/coverage-of-weight-loss-drugs-by-medicaid-plans-continues-to-lag/#:~:text=Medicaid%2C%20a%20federal,employees%20due%20to%20cost%20concerns
• https://www.fiercepharma.com/marketing/novo-unveils-newly-reduced-self-pay-prices-wegovy-ozempic-after-white-house-deal#:~:text=Novo%20revealed%20Monday%20that%20the,will%20still%20run%20for%20%24499